Physician profile
Eric E Mcclendon
NPI 1841566288
$11,798.86
in general payments reported to CMS, 2019-2025
26 companies · $1,563 in 2025
The $1,563 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $562 · 2020: $3,148 · 2021: $1,631 · 2022: $810 · 2023: $3,186 · 2024: $898 · 2025: $1,563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,949 · Travel and Lodging: $2,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,949.39 |
| Travel and Lodging | $2,698.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,453.59 | 2019-2025 | Versacross Access Solution, General - Therapies, Eluvia |
| Abiomed | $1,992.58 | 2023-2025 | Impella |
| Medtronic Vascular, INC. | $1,622.15 | 2019-2020 | |
| Edwards Lifesciences Corporation | $1,551.05 | 2020-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medtronic, INC. | $1,433.54 | 2021-2025 | Symplicity G3, Onyx Frontier, Hawkone |
| Abbott Laboratories | $607.47 | 2019-2025 | Mitraclip, Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $415.03 | 2021-2023 | Lifevest |
| Novartis Pharmaceuticals Corporation | $363.92 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $322.09 | 2020-2024 | Farxiga |
| Amgen INC. | $269.70 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $188.90 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $113.79 | 2022-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $80.59 | 2022-2023 | Xarelto |
| Terumo Medical Corporation | $63.45 | 2021-2024 | Glidewire, Navicross |
| Merck Sharp & Dohme LLC | $50.70 | 2023 | Verquvo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $46.45 | 2025 | Penumbra System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.95 | 2021-2023 | Jardiance |
| W. L. Gore & Associates, INC. | $33.74 | 2021-2025 | Gore Cardioform Septal Occluder |
| Chiesi USA, INC. | $23.75 | 2021 | |
| Angiodynamics, INC. | $20.53 | 2024 | Auryon Laser System 100-120 Vac |
| Novo Nordisk INC | $18.89 | 2023 | Ozempic, Rybelsus |
| Heartflow, INC. | $17.25 | 2024 | |
| Gilead Sciences, INC. | $17.07 | 2019 | |
| Akcea Therapeutics, INC. | $16.85 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $16.04 | 2025 | Exparel |
| Philips North America LLC | $14.79 | 2025 | Azurion 7 M20 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Mcclendon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.